Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800454 | 1.00 | HPGD (0.47) | HPGDKDM4ENPC1RAB9AMAPT | |
| SCHEMBL4796722 | 0.87 | HSD17B3 (0.56) | HPGDKDM4ENPC1RAB9AMAPT | |
| SCHEMBL4796728 | 0.87 | HSD17B3 (0.56) | HPGDKDM4ENPC1RAB9AMAPT | |
| SCHEMBL14084550 | 0.86 | HSD17B3 (0.48) | HSD17B3HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4798501 | 0.84 | HSD17B3 (0.46) | KDM4EHSD17B3NAMPTALDH1A1GAA | |
| SCHEMBL4798512 | 0.84 | HSD17B3 (0.46) | KDM4EHSD17B3NAMPTALDH1A1GAA | |
| SCHEMBL14084547 | 0.83 | NAMPT (0.49) | HPGDHSD17B3NAMPTGAA | |
| SCHEMBL14084553 | 0.82 | HSD17B3 (0.45) | HSD17B3NAMPTSMN1; SMN2ALDH1A1P2RX4 | |
| SCHEMBL4800970 | 0.82 | HSD17B3 (0.63) | HPGDKDM4ENPC1RAB9AMAPT | |
| SCHEMBL14084552 | 0.81 | HSD17B3 (0.44) | HPGDHSD17B3NAMPTGAAP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HPGD 34/4885KDM4E 3392/4885NPC1 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.